

CARACTERIZACIÓN BIOLÓGICA DE LA LEUCEMIA MIELOIDE
AGUDA CON TRANSLOCACIÓN t(8;16)(p11;p13) Y
REORDENAMIENTO *MYST3-CREBBP*

Tesi presentada per
Mireia Camós Guijosa
per aspirar al grau de Doctora en Medicina

Director de la tesi Dr. Jordi Esteve i Reyner

Facultat de Medicina
Universitat de Barcelona
Tutor de la tesi: Prof. Emili Montserrat i Costa

Barcelona, 2007

VIII. BIBLIOGRAFÍA

Bibliografía

- Aguiar, RC; Chase, A; Coulthard, S; Macdonald, DH; Carapeti, M; Reiter, A; Sohal, J; Lennard, A; Goldman, JM, and Cross, NC. (1997). Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. *Blood* (90) 3130-3135.
- Alcalay, M; Tiacci, E; Bergomas, R; Bigerna, B; Venturini, E; Minardi, SP; Meani, N; Diverio, D; Bernard, L; Tizzoni, L; Volorio, S; Luzi, L; Colombo, E; Lo Coco, F; Mecucci, C; Falini, B, and Pelicci, PG. (2005). Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* (106) 899-902.
- Ales, N; Flynn, J, and Byrd, JC. (2001). Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea. *Ann. Intern. Med.* (135) 303-304.
- Andersen, MK; Christiansen, DH; Kirchhoff, M, and Pedersen-Bjergaard, J. (2001). Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. *Genes Chromosomes. Cancer* (31) 33-41.
- Aoudjhane, M; Labopin, M; Gorin, NC; Shimoni, A; Ruutu, T; Kolb, HJ; Frassoni, F; Boiron, JM; Yin, JL; Finke, J; Shouten, H; Blaise, D; Falda, M; Fauser, AA; Esteve, J; Polge, E; Slavin, S; Niederwieser, D; Nagler, A, and Rocha, V. (2005). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). *Leukemia* (19) 2304-2312.
- Arbuthnot, C and Wilde, JT. (2006). Haemostatic problems in acute promyelocytic leukaemia. *Blood Rev.*
- Armstrong, SA; Golub, TR, and Korsmeyer, SJ. (2003a). MLL-rearranged leukemias: insights from gene expression profiling. *Semin. Hematol.* (40) 268-273.
- Armstrong, SA; Kung, AL; Mabon, ME; Silverman, LB; Stam, RW; den Boer, ML; Pieters, R; Kersey, JH; Sallan, SE; Fletcher, JA; Golub, TR; Griffin, JD, and Korsmeyer, SJ. (2003b). Inhibition of FLT3 in MLL. Validation of a

therapeutic target identified by gene expression based classification. *Cancer Cell* (3) 173-183.

Armstrong, SA; Staunton, JE; Silverman, LB; Pieters, R; den Boer, ML; Minden, MD; Sallan, SE; Lander, ES; Golub, TR, and Korsmeyer, SJ. (2002). MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat. Genet.* (30) 41-47.

Ayton, PM and Cleary, ML. (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. *Genes & Dev.* (17) 2298-2307.

Bacher, U; Haferlach, T; Schoch, C; Kern, W, and Schnittger, S. (2006). Implications of NRAS mutations in AML: a study of 2502 patients. *Blood* (107) 3847-3853.

Bagby, GC and Alter, BP. (2006). Fanconi anemia. *Semin. Hematol.* (43) 147-156.

Baldus, CD; Thiede, C; Soucek, S; Bloomfield, CD; Thiel, E, and Ehninger, G. (2006). BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. *J. Clin. Oncol.* (24) 790-797.

Barjesteh van Waalwijk van Doorn-Khosrovani; Erpelinck, C; Meijer, J; van Oosterhoud, S; van Putten, WL; Valk, PJ; Berna, BH; Tenen, DG; Lowenberg, B, and Delwel, R. (2003a). Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. *Hematol. J.* (4) 31-40.

Barjesteh van Waalwijk van Doorn-Khosrovani; Erpelinck, C; van Putten, WL; Valk, PJ; van der Poel-van de Luytgaarde; Hack, R; Slater, R; Smit, EM; Beverloo, HB; Verhoef, G; Verdonck, LF; Ossenkoppele, GJ; Sonneveld, P; de Greef, GE; Lowenberg, B, and Delwel, R. (2003b). High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. *Blood* (101) 837-845.

Benekli, M; Baer, MR; Baumann, H, and Wetzler, M. (2003). Signal transducer and activator of transcription proteins in leukemias. *Blood* (101) 2940-2954.

Benekli, M; Xia, Z; Donohue, KA; Ford, LA; Pixley, LA; Baer, MR; Baumann, H, and Wetzler, M. (2002). Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. *Blood* (99) 252-257.

- Bennett, JM; Catovsky, D; Daniel, MT; Flandrin, G; Galton, DA; Gralnick, HR, and Sultan, C. (1976). Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br. J. Haematol.* (33) 451-458.
- Bennett, JM; Catovsky, D; Daniel, MT; Flandrin, G; Galton, DA; Gralnick, HR, and Sultan, C. (1985). Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. *Ann. Intern. Med.* (103) 460-462.
- Bennett, JM; Catovsky, D; Daniel, MT; Flandrin, G; Galton, DA; Gralnick, HR, and Sultan, C. (1991). Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). *Br. J. Haematol.* (78) 325-329.
- Bernasconi, P; Orlandi, E; Cavigliano, P; Calatroni, S; Boni, M; Astori, C; Pagnucco, G; Giglio, S; Caresana, M; Lazzarino, M, and Bernasconi, C. (2000). Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma. *Haematologica* (85) 1087-1091.
- Birkenkamp, KU; Geugien, M; Lemmink, HH; Kruijer, W, and Vellenga, E. (2001). Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. *Leukemia* (15) 1923-1931.
- Bloomfield, CD; Lawrence, D; Byrd, JC; Carroll, A; Pettenati, MJ; Tantravahi, R; Patil, SR; Davey, FR; Berg, DT; Schiffer, CA; Arthur, DC, and Mayer, RJ. (1998). Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. *Cancer Res.* (58) 4173-4179.
- Bloomfield, CD; Ruppert, AS; Mrozek, K; Kolitz, JE; Moore, JO; Mayer, RJ; Edwards, CG; Sterling, LJ; Vardiman, JW; Carroll, AJ; Pettenati, MJ; Stamberg, J; Byrd, JC; Marcucci, G, and Larson, RA. (2004). Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. *Ann. Hematol.* (83 Suppl 1) S84-S85.
- Blyth, K; Cameron, ER, and Neil, JC. (2005). The RUNX genes: gain or loss of function in cancer. *Nat. Rev. Cancer* (5) 376-387.
- Boissel, N; Leroy, H; Brethon, B; Philippe, N; de Botton, S; Auvrignon, A; Raffoux, E; Leblanc, T; Thomas, X; Hermine, O; Quesnel, B; Baruchel, A; Leverger, G; Dombret, H, and Preudhomme, C. (2006). Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). *Leukemia* (20) 965-970.

- Boisvert, FM; Kruhlak, MJ; Box, AK; Hendzel, MJ, and Bazett-Jones, DP. (2001). The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. *J. Cell Biol.* (152) 1099-1106.
- Bole-Feysot, C; Goffin, V; Edery, M; Binart, N, and Kelly, PA. (1998). Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. *Endocr. Rev.* (19) 225-268.
- Borrow, J; Stanton, VP, Jr.; Andresen, JM; Becher, R; Behm, FG; Chaganti, RS; Civin, CI; Distech, C; Dube, I; Frischauf, AM; Horsman, D; Mitelman, F; Volinia, S; Watmore, AE, and Housman, DE. (1996). The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. *Nat. Genet.* (14) 33-41.
- Bowen, DT; Frew, ME; Hills, R; Gale, RE; Wheatley, K; Groves, MJ; Langabeer, SE; Kottaridis, PD; Moorman, AV; Burnett, AK, and Linch, DC. (2005). RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. *Blood* (106) 2113-2119.
- Brunet, S; Esteve, J; Berlanga, J; Ribera, JM; Bueno, J; Marti, JM; Bargay, J; Guardia, R; Julia, A; Granena, A; Montserrat, E, and Sierra, J. (2004). Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. *Haematologica* (89) 940-949.
- bu-Duhier, FM; Goodeve, AC; Wilson, GA; Gari, MA; Peake, IR; Rees, DC; Vandenberghe, EA; Winship, PR, and Reilly, JT. (2000). FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. *Br. J. Haematol.* (111) 190-195.
- Bullinger, L; Dohner, K; Bair, E; Frohling, S; Schlenk, RF; Tibshirani, R; Dohner, H, and Pollack, JR. (2004). Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. *N. Engl. J. Med.* (350) 1605-1616.
- Burnett, AK; Grimwade, D; Solomon, E; Wheatley, K, and Goldstone, AH. (1999). Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. *Blood* (93) 4131-4143.
- Byrd, JC; Dodge, RK; Carroll, A; Baer, MR; Edwards, C; Stamberg, J; Qumsiyeh, M; Moore, JO; Mayer, RJ; Davey, F; Schiffer, CA, and Bloomfield, CD. (1999). Patients with t(8;21)(q22;q22) and acute myeloid leukemia

have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. *J. Clin. Oncol.* (17) 3767-3775.

Byrd, JC; Mrozek, K; Dodge, RK; Carroll, AJ; Edwards, CG; Arthur, DC; Pettenati, MJ; Patil, SR; Rao, KW; Watson, MS; Koduru, PR; Moore, JO; Stone, RM; Mayer, RJ; Feldman, EJ; Davey, FR; Schiffer, CA; Larson, RA, and Bloomfield, CD. (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood* (100) 4325-4336.

Byrd, JC; Ruppert, AS; Mrozek, K; Carroll, AJ; Edwards, CG; Arthur, DC; Pettenati, MJ; Stamberg, J; Koduru, PR; Moore, JO; Mayer, RJ; Davey, FR; Larson, RA, and Bloomfield, CD. (2004). Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. *J. Clin. Oncol.* (22) 1087-1094.

Callens, C; Chevret, S; Cayuela, JM; Cassinat, B; Raffoux, E; de Botton, S; Thomas, X; Guerci, A; Fegueux, N; Pigneux, A; Stoppa, AM; Lamy, T; Rigal-Huguet, F; Vekhoff, A; Meyer-Monard, S; Ferrand, A; Sanz, M; Chomienne, C; Fenaux, P, and Dombret, H. (2005). Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. *Leukemia* (19) 1153-1160.

Carapeti, M; Aguiar, RC; Goldman, JM, and Cross, NC. (1998). A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. *Blood* (91) 3127-3133.

Care, RS; Valk, PJ; Goodeve, AC; Abu-Duhier, FM; Geertsma-Kleinekoort, WM; Wilson, GA; Gari, MA; Peake, IR; Lowenberg, B, and Reilly, JT. (2003). Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. *Br. J. Haematol.* (121) 775-777.

Cassileth, PA; Harrington, DP; Appelbaum, FR; Lazarus, HM; Rowe, JM; Paietta, E; Willman, C; Hurd, DD; Bennett, JM; Blume, KG; Head, DR, and Wiernik, PH. (1998). Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *N. Engl. J. Med.* (339) 1649-1656.

Chaffanet, M; Gressin, L; Preudhomme, C; Soenen-Cornu, V; Birnbaum, D, and Pebusque, MJ. (2000). MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). *Genes Chromosomes. Cancer* (28) 138-144.

- Chaffanet, M; Mozziconacci, MJ; Fernandez, F; Sainty, D; Lafage-Pochitaloff, M; Birnbaum, D, and Pebusque, MJ. (1999). A case of inv(8)(p11q24) associated with acute myeloid leukemia involves the MOZ and CBP genes in a masked t(8;16). *Genes Chromosomes. Cancer* (26) 161-165.
- Champagne, N; Bertos, NR; Pelletier, N; Wang, AH; Vezmar, M; Yang, Y; Heng, HH, and Yang, XJ. (1999). Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. *J. Biol. Chem.* (274) 28528-28536.
- Champagne, N; Pelletier, N, and Yang, XJ. (2001). The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. *Oncogene* (20) 404-409.
- Chen, W; Rassidakis, GZ; Li, J; Routbort, M; Jones, D; Kantarjian, H; Medeiros, LJ, and Bueso-Ramos, CE. (2006). High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). *Blood* (108) 1783-1784.
- Cheson, BD; Bennett, JM; Kopecky, KJ; Buchner, T; Willman, CL; Estey, EH; Schiffer, CA; Doehner, H; Tallman, MS; Lister, TA; Lo Coco, F; Willemze, R; Biondi, A; Hiddemann, W; Larson, RA; Lowenberg, B; Sanz, MA; Head, DR; Ohno, R, and Bloomfield, CD. (2003). Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J. Clin. Oncol.* (21) 4642-4649.
- Cilloni, D; Carturan, S; Gottardi, E; Messa, F; Messa, E; Fava, M; Diverio, D; Guerrasio, A; Lo Coco, F, and Saglio, G. (2003). Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. *Blood* (102) 2705-2706.
- Collins, HM; Kindle, KB; Matsuda, S; Ryan, C; Troke, PJ; Kalkhoven, E, and Heery, DM. (2006b). MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators. *J. Biol. Chem.* (281) 17124-17133.
- Collins, HM; Kindle, KB; Matsuda, S; Ryan, C; Troke, PJ; Kalkhoven, E, and Heery, DM. (2006a). MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators. *J. Biol. Chem.* (281) 17124-17133.

- Cornelissen, JJ and Lowenberg, B. (2005). Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. *Hematology. Am. Soc. Hematol. Educ. Program.* 151-155.
- Daser, A and Rabbitts, TH. (2004). Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. *Genes & Dev.* (18) 965-974.
- de Botton, S; Fawaz, A; Chevret, S; Dombret, H; Thomas, X; Sanz, M; Guerci, A; San Miguel, JF; De La Serna, J; Stoppa, AM; Reman, O; Stamatoulas, A; Fey, M; Cahn, JY; Sotto, JJ; Bourhis, JH; Parry, A; Chomienne, C; Degos, L, and Fenaux, P. (2005). Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. *J. Clin. Oncol.* (23) 120-126.
- Debernardi, S; Lillington, DM; Chaplin, T; Tomlinson, S; Amess, J; Rohatiner, A; Lister, TA, and Young, BD. (2003). Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. *Genes Chromosomes. Cancer* (37) 149-158.
- Demuyne, H; Verhoef, GE; Zachee, P; Vandenberghe, P; Van Orshoven, A; Paridaens, R; Samson, I, and Boogaerts, MA. (1995). Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma. *Cancer Genet. Cytogenet.* (82) 103-105.
- Dohner, K; Schlenk, RF; Habdank, M; Scholl, C; Rucker, FG; Corbacioglu, A; Bullinger, L; Frohling, S, and Dohner, H. (2005). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. *Blood* (106) 3740-3746.
- Dohner, K; Tobis, K; Ulrich, R; Frohling, S; Benner, A; Schlenk, RF, and Dohner, H. (2002). Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. *J. Clin. Oncol.* (20) 3254-3261.
- Dolan, M; McGlennen, RC, and Hirsch, B. (2002). MLL amplification in myeloid malignancies: clinical, molecular, and cytogenetic findings. *Cancer Genet. Cytogenet.* (134) 93-101.
- Dong, F; Brynes, RK; Tidow, N; Welte, K; Lowenberg, B, and Touw, IP. (1995). Mutations in the gene for the granulocyte colony-stimulating-factor

receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. *N. Engl. J. Med.* (333) 487-493.

Downing, JR. (1999). The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. *Br. J. Haematol.* (106) 296-308.

Drabkin, HA; Parsy, C; Ferguson, K; Guilhot, F; Lacotte, L; Roy, L; Zeng, C; Baron, A; Hunger, SP; Varella-Garcia, M; Gemmill, R; Brizard, F; Brizard, A, and Roche, J. (2002). Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. *Leukemia* (16) 186-195.

Drexler, HG. (1996). Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. *Leukemia* (10) 588-599.

Dunphy, CH. (2006). Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. *Arch. Pathol. Lab Med.* (130) 483-520.

Durst, KL; Lutterbach, B; Kummalu, T; Friedman, AD, and Hiebert, SW. (2003). The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. *Mol. Cell Biol.* (23) 607-619.

Ebert, BL and Golub, TR. (2004). Genomic approaches to hematologic malignancies. *Blood* (104) 923-932.

Esteve, J; Escoda, L; Martin, G; Rubio, V; Díaz-Mediavilla, J; Gonzalez, M; Rivas, C; Alvarez, C; Gonzalez San Miguel, JD; Brunet, S; Tomas, JF; Tormo, M; Sayas, MJ; Sanchez, GP; Colomer, D; Bolufer, P, and Sanz, MA. (2007). Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. *Leukemia*

Estey, EH; Giles, FJ; Beran, M; O'Brien, S; Pierce, SA; Faderl, SH; Cortes, JE, and Kantarjian, HM. (2002). Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. *Blood* (99) 4222-4224.

Falini, B; Mecucci, C; Tiacci, E; Alcalay, M; Rosati, R; Pasqualucci, L; La Starza, R; Diverio, D; Colombo, E; Santucci, A; Bigerna, B; Pacini, R; Pucciarini, A; Liso, A; Vignetti, M; Fazi, P; Meani, N; Pettirossi, V; Saglio, G; Mandelli, F; Lo Coco, F; Pelicci, PG, and Martelli, MF. (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N. Engl. J. Med.* (352) 254-266.

- Fenaux, P; Chastang, C; Chevret, S; Sanz, M; Dombret, H; Archimbaud, E; Fey, M; Rayon, C; Huguet, F; Sotto, JJ; Gardin, C; Makhoul, PC; Travade, P; Solary, E; Fegueux, N; Bordessoule, D; Miguel, JS; Link, H; Desablens, B; Stamatoullas, A; Deconinck, E; Maloisel, F; Castaigne, S; Preudhomme, C, and Degos, L. (1999). A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. *Blood* (94) 1192-1200.
- First MIC Cooperative Study Group. (1986). Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias. Report of the workshop held in Leuven, Belgium, April 22-23, 1985. First MIC Cooperative Study Group. *Cancer Genet. Cytogenet.* (23) 189-197.
- Frohling, S; Schlenk, RF; Breitruock, J; Benner, A; Kreitmeier, S; Tobis, K; Dohner, H, and Dohner, K. (2002). Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood* (100) 4372-4380.
- Frohling, S; Schlenk, RF; Stolze, I; Bihlmayr, J; Benner, A; Kreitmeier, S; Tobis, K; Dohner, H, and Dohner, K. (2004). CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. *J. Clin. Oncol.* (22) 624-633.
- Frohling, S; Scholl, C; Gilliland, DG, and Levine, RL. (2005). Genetics of myeloid malignancies: pathogenetic and clinical implications. *J. Clin. Oncol.* (23) 6285-6295.
- Gale, RE; Hills, R; Pizzey, AR; Kottaridis, PD; Swirsky, D; Gilkes, AF; Nugent, E; Mills, KI; Wheatley, K; Solomon, E; Burnett, AK; Linch, DC, and Grimwade, D. (2005). Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. *Blood* (106) 3768-3776.
- Gattei, V; Degan, M; Aldinucci, D; De luliis, A; Rossi, FM; Mazzocco, FT; Rupolo, M; Zagonel, V, and Pinto, A. (1998). Differential expression of the RET gene in human acute myeloid leukemia. *Ann. Hematol.* (77) 207-210.
- Gattei, V; Degan, M; Rossi, FM; De luliis, A; Mazzocco, FT; Cesa, E; Aldinucci, D; Zagonel, V, and Pinto, A. (1999). The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. *Br. J. Haematol.* (105) 225-240.

- Giles, RH; Dauwerse, JG; Higgins, C; Petrij, F; Wessels, JW; Beverstock, GC; Dohner, H; Jotterand-Bellomo, M; Falkenburg, JH; Slater, RM; van Ommen, GJ; Hagemeijer, A; van der Reijden, BA, and Breuning, MH. (1997). Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16). *Leukemia* (11) 2087-2096.
- Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD, and Lander, ES. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* (286) 531-537.
- Grier, DG; Thompson, A; Kwasniewska, A; McGonigle, GJ; Halliday, HL, and Lappin, TR. (2005). The pathophysiology of HOX genes and their role in cancer. *J. Pathol.* (205) 154-171.
- Grimwade, D; Walker, H; Harrison, G; Oliver, F; Chatters, S; Harrison, CJ; Wheatley, K; Burnett, AK, and Goldstone, AH. (2001). The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* (98) 1312-1320.
- Grimwade, D; Walker, H; Oliver, F; Wheatley, K; Harrison, C; Harrison, G; Rees, J; Hann, I; Stevens, R; Burnett, A, and Goldstone, A. (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. *Blood* (92) 2322-2333.
- Grisendi, S; Mecucci, C; Falini, B, and Pandolfi, PP. (2006). Nucleophosmin and cancer. *Nat. Rev. Cancer* (6) 493-505.
- Grisendi, S and Pandolfi, PP. (2005). NPM mutations in acute myelogenous leukemia. *N. Engl. J. Med.* (352) 291-292.
- Gutierrez, NC; Lopez-Perez, R; Hernandez, JM; Isidro, I; Gonzalez, B; Delgado, M; Ferminan, E; Garcia, JL; Vazquez, L; Gonzalez, M, and San Miguel, JF. (2005). Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. *Leukemia* (19) 402-409.
- Haferlach, T; Kohlmann, A; Kern, W; Hiddemann, W; Schnittger, S, and Schoch, C. (2003). Gene expression profiling as a tool for the diagnosis of acute leukemias. *Semin. Hematol.* (40) 281-295.

- Haferlach, T; Kohlmann, A; Schnittger, S; Dugas, M; Hiddemann, W; Kern, W, and Schoch, C. (2005a). AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. *Genes Chromosomes. Cancer* (43) 113-127.
- Haferlach, T; Kohlmann, A; Schnittger, S; Dugas, M; Hiddemann, W; Kern, W, and Schoch, C. (2005b). Global approach to the diagnosis of leukemia using gene expression profiling. *Blood* (106) 1189-1198.
- Hanslip, J; Swansbury, G; Pinkerton, R, and Catovsky, D. (1992). The translocation t(8;16)(p11;p13) defines an AML subtype with distinct cytology and clinical features. *Leuk. Lymphoma* (6) 479-486.
- Harris, NL; Jaffe, ES; Diebold, J; Flandrin, G; Muller-Hermelink, HK; Vardiman, J; Lister, TA, and Bloomfield, CD. (1999). The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. *Ann. Oncol.* (10) 1419-1432.
- Hatfill, SJ; Kirby, R; Hanley, M; Rybicki, E, and Bohm, L. (1990). Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4. *Leuk. Res.* (14) 57-62.
- Hayakawa, F; Towatari, M; Kiyoi, H; Tanimoto, M; Kitamura, T; Saito, H, and Naoe, T. (2000). Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. *Oncogene* (19) 624-631.
- Herr, AL; Labopin, M; Blaise, D; Milpied, N; Potter, M; Michallet, M; Heit, W; Ferrara, F; Esteve, J; Arcese, W; Ehninger, G; Rowe, JM; Kobbe, G; Rosselet, A; Bunjes, D; Rio, B; Brune, M; Nagler, A; Gorin, NC; Frassoni, F, and Rocha, V. (2007). HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. *Leukemia* (21) 129-135.
- Hiddemann, W; Spiekermann, K; Buske, C; Feuring-Buske, M; Braess, J; Haferlach, T; Schoch, C; Kern, W; Schnittger, S; Berdel, W; Wormann, B; Heinecke, A; Sauerland, C, and Buchner, T. (2005). Towards a pathogenesis-oriented therapy of acute myeloid leukemia. *Crit Rev. Oncol. Hematol.* (56) 235-245.

- Hiebert, SW; Reed-Inderbitzin, EF; Amann, J; Irvin, B; Durst, K, and Linggi, B. (2003). The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor. *Blood Cells Mol. Dis.* (30) 177-183.
- Jacobson, S and Pillus, L. (1999). Modifying chromatin and concepts of cancer. *Curr. Opin. Genet. Dev.* (9) 175-184.
- Kalkhoven, E. (2004). CBP and p300: HATs for different occasions. *Biochem. Pharmacol.* (68) 1145-1155.
- Kalkhoven, E; Roelfsema, JH; Teunissen, H; den Boer, A; Ariyurek, Y; Zantema, A; Breuning, MH; Hennekam, RC, and Peters, DJ. (2003). Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. *Hum. Mol. Genet.* (12) 441-450.
- Kanno, Y; Kanno, T; Sakakura, C; Bae, SC, and Ito, Y. (1998). Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. *Mol. Cell Biol.* (18) 4252-4261.
- Kasper, LH; Brindle, PK; Schnabel, CA; Pritchard, CE; Cleary, ML, and van Deursen, JM. (1999). CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOX9 oncogenicity. *Mol. Cell Biol.* (19) 764-776.
- Katsumoto, T; Aikawa, Y; Iwama, A; Ueda, S; Ichikawa, H; Ochiya, T, and Kitabayashi, I. (2006). MOZ is essential for maintenance of hematopoietic stem cells. *Genes Dev.* (20) 1321-1330.
- Kell, WJ; Burnett, AK; Chopra, R; Yin, JA; Clark, RE; Rohatiner, A; Culligan, D; Hunter, A; Prentice, AG, and Milligan, DW. (2003). A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. *Blood* (102) 4277-4283.
- Kern, W and Estey, EH. (2006). High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. *Cancer* (107) 116-124.
- Kindle, KB; Troke, PJ; Collins, HM; Matsuda, S; Bossi, D; Bellodi, C; Kalkhoven, E; Salomoni, P; Pelicci, PG; Minucci, S, and Heery, DM. (2005a). MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. *Mol. Cell Biol.* (25) 988-1002.

- Kindle, KB; Troke, PJ; Collins, HM; Matsuda, S; Bossi, D; Bellodi, C; Kalkhoven, E; Salomoni, P; Pelicci, PG; Minucci, S, and Heery, DM. (2005b). MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. *Mol. Cell Biol.* (25) 988-1002.
- Kitabayashi, I; Aikawa, Y; Nguyen, LA; Yokoyama, A, and Ohki, M. (2001a). Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. *EMBO J.* (20) 7184-7196.
- Kitabayashi, I; Aikawa, Y; Yokoyama, A; Hosoda, F; Nagai, M; Kakazu, N; Abe, T, and Ohki, M. (2001b). Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. *Leukemia* (15) 89-94.
- Kiyoi, H and Naoe, T. (2006). Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. *Int. J. Hematol.* (83) 301-308.
- Kiyoi, H; Naoe, T; Nakano, Y; Yokota, S; Minami, S; Miyawaki, S; Asou, N; Kuriyama, K; Jinnai, I; Shimazaki, C; Akiyama, H; Saito, K; Oh, H; Motoji, T; Omoto, E; Saito, H; Ohno, R, and Ueda, R. (1999). Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. *Blood* (93) 3074-3080.
- Kiyoi, H; Towatari, M; Yokota, S; Hamaguchi, M; Ohno, R; Saito, H, and Naoe, T. (1998). Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. *Leukemia* (12) 1333-1337.
- Klampfer, L; Zhang, J; Zelenetz, AO; Uchida, H, and Nimer, SD. (1996). The AML1/ETO fusion protein activates transcription of BCL-2. *Proc. Natl. Acad. Sci. U. S. A* (93) 14059-14064.
- Kohler, T; Schill, C; Deininger, MW; Krahl, R; Borchert, S; Hasenclever, D; Leiblein, S; Wagner, O, and Niederwieser, D. (2002). High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). *Leukemia* (16) 22-29.
- Kohlmann, A; Schoch, C; Dugas, M; Schnittger, S; Hiddemann, W; Kern, W, and Haferlach, T. (2005). New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. *Leukemia* (19) 953-964.
- Kohlmann, A; Schoch, C; Schnittger, S; Dugas, M; Hiddemann, W; Kern, W, and Haferlach, T. (2003). Molecular characterization of acute leukemias by use of microarray technology. *Genes Chromosomes. Cancer* (37) 396-405.

- Kooijman, R; Gerlo, S; Coppens, A, and Hooghe-Peters, EL. (2000). Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin. *J. Neuroimmunol.* (110) 252-258.
- Kottaridis, PD; Gale, RE; Frew, ME; Harrison, G; Langabeer, SE; Belton, AA; Walker, H; Wheatley, K; Bowen, DT; Burnett, AK; Goldstone, AH, and Linch, DC. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood* (98) 1752-1759.
- Kuchenbauer, F; Schoch, C; Kern, W; Hiddemann, W; Haferlach, T, and Schnittger, S. (2005). Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. *Br. J. Haematol.* (130) 196-202.
- Kung, AL; Rebel, VI; Bronson, RT; Ch'ng, LE; Sieff, CA; Livingston, DM, and Yao, TP. (2000). Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. *Genes & Dev.* (14) 272-277.
- LaMorte, VJ; Dyck, JA; Ochs, RL, and Evans, RM. (1998). Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. *Proc. Natl. Acad. Sci. U. S. A* (95) 4991-4996.
- Leith, CP; Kopecky, KJ; Chen, IM; Eijdem, L; Slovak, ML; McConnell, TS; Head, DR; Weick, J; Grever, MR; Appelbaum, FR, and Willman, CL. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. *Blood* (94) 1086-1099.
- Lengfelder, E; Reichert, A; Schoch, C; Haase, D; Haferlach, T; Loffler, H; Staib, P; Heyll, A; Seifarth, W; Saussele, S; Fonatsch, C; Gassmann, W; Ludwig, WD; Hochhaus, A; Beelen, D; Aul, C; Sauerland, MC; Heinecke, A; Hehlmann, R; Wormann, B; Hiddemann, W, and Buchner, T. (2000). Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. *Leukemia* (14) 1362-1370.
- Leroy, H; Roumier, C; Huyghe, P; Biggio, V; Fenaux, P, and Preudhomme, C. (2005). CEBPA point mutations in hematological malignancies. *Leukemia* (19) 329-334.

- Liang, J; Prouty, L; Williams, BJ; Dayton, MA, and Blanchard, KL. (1998). Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. *Blood* (92) 2118-2122.
- Libura, M; Asnafi, V; Tu, A; Delabesse, E; Tigaud, I; Cymbalista, F; naceur-Griscelli, A; Villarese, P; Solbu, G; Hagemeyer, A; Beldjord, K; Hermine, O, and Macintyre, E. (2003). FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. *Blood* (102) 2198-2204.
- Lo Coco, F; Ammatuna, E, and Noguera, N. (2006). Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. *Clin. Adv. Hematol. Oncol.* (4) 57-57.
- Lo Coco, F; Romano, A; Mengarelli, A; Diverio, D; Iori, AP; Moleti, ML; De Santis, S; Cerretti, R; Mandelli, F, and Arcese, W. (2003). Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. *Leukemia* (17) 1930-1933.
- Lowenberg, B; Downing, JR, and Burnett, A. (1999). Acute myeloid leukemia. *N. Engl. J. Med.* (341) 1051-1062.
- Lowenberg, B; van Putten, WL; Theobald, M; Gmur, J; Verdonck, L; Sonneveld, P; Fey, M; Schouten, H; de Greef, GE; Ferrant, A; Kovacsovics, T; Gratwohl, A; Daenen, S; Huijgens, P, and Boogaerts, M. (2003). Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. *N. Engl. J. Med.* (349) 743-752.
- Mahadevan, D and List, AF. (2004). Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. *Blood* (104) 1940-1951.
- Mandelli, F; Diverio, D; Avvisati, G; Luciano, A; Barbui, T; Bernasconi, C; Broccia, G; Cerri, R; Falda, M; Fioritoni, G; Leoni, F; Liso, V; Petti, MC; Rodeghiero, F; Saglio, G; Vegna, ML; Visani, G; Jehn, U; Willemze, R; Muus, P; Pelicci, PG; Biondi, A, and Lo Coco, F. (1997). Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. *Blood* (90) 1014-1021.
- Marcucci, G; Baldus, CD; Ruppert, AS; Radmacher, MD; Mrozek, K; Whitman, SP; Kolitz, JE; Edwards, CG; Vardiman, JW; Powell, BL; Baer, MR; Moore, JO; Perrotti, D; Caligiuri, MA; Carroll, AJ; Larson, RA; de la

- Chapelle, A, and Bloomfield, CD. (2005a). Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. *J. Clin. Oncol.* (23) 9234-9242.
- Marcucci, G; Baldus, CD; Ruppert, AS; Radmacher, MD; Mrozek, K; Whitman, SP; Kolitz, JE; Edwards, CG; Vardiman, JW; Powell, BL; Baer, MR; Moore, JO; Perrotti, D; Caligiuri, MA; Carroll, AJ; Larson, RA; de la Chapelle, A, and Bloomfield, CD. (2005b). Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. *J. Clin. Oncol.* (23) 9234-9242.
- Margalit, O; Somech, R; Amariglio, N, and Rechavi, G. (2005). Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. *Blood Rev.* (19) 223-234.
- Martin, ME; Milne, TA; Bloyer, S; Galoian, K; Shen, W; Gibbs, D; Brock, HW; Slany, R, and Hess, JL. (2003). Dimerization of MLL fusion proteins immortalizes hematopoietic cells. *Cancer Cell* (4) 197-207.
- Menell, JS; Cesarman, GM; Jacovina, AT; McLaughlin, MA; Lev, EA, and Hajjar, KA. (1999). Annexin II and bleeding in acute promyelocytic leukemia. *N. Engl. J. Med.* (340) 994-1004.
- Messner, HA. (2006). How good is allogeneic transplantation for high-risk patients with AML? *Best. Pract. Res. Clin. Haematol.* (19) 329-332.
- Miller, CT; Maves, L, and Kimmel, CB. (2004). *moz* regulates Hox expression and pharyngeal segmental identity in zebrafish. *Development* (131) 2443-2461.
- Milne, TA; Briggs, SD; Brock, HW; Martin, ME; Gibbs, D; Allis, CD, and Hess, JL. (2002). MLL targets SET domain methyltransferase activity to Hox gene promoters. *Mol. Cell* (10) 1107-1117.
- Milne, TA; Hughes, CM; Lloyd, R; Yang, Z; Rozenblatt-Rosen, O; Dou, Y; Schnepf, RW; Krankel, C; Livolsi, VA; Gibbs, D; Hua, X; Roeder, RG; Meyerson, M, and Hess, JL. (2005). Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. *Proc. Natl. Acad. Sci. U. S. A* (102) 749-754.
- Minami, Y; Yamamoto, K; Kiyoi, H; Ueda, R; Saito, H, and Naoe, T. (2003). Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. *Blood* (102) 2969-2975.

- Mistry, AR; Felix, CA; Whitmarsh, RJ; Mason, A; Reiter, A; Cassinat, B; Parry, A; Walz, C; Wiemels, JL; Segal, MR; Ades, L; Blair, IA; Osheroff, N; Peniket, AJ; Lafage-Pochitaloff, M; Cross, NC; Chomienne, C; Solomon, E; Fenaux, P, and Grimwade, D. (2005). DNA topoisomerase II in therapy-related acute promyelocytic leukemia. *N. Engl. J. Med.* (352) 1529-1538.
- Mohty, M; de Lavallade, H; Ladaïque, P; Faucher, C; Vey, N; Coso, D; Stoppa, AM; Gastaut, JA, and Blaise, D. (2005). The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. *Leukemia* (19) 916-920.
- Moreno, I; Martin, G; Bolufer, P; Barragan, E; Rueda, E; Roman, J; Fernandez, P; Leon, P; Mena, A; Cervera, J; Torres, A, and Sanz, MA. (2003). Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. *Haematologica* (88) 19-24.
- Mrozek, K; Heerema, NA, and Bloomfield, CD. (2004). Cytogenetics in acute leukemia. *Blood Rev.* (18) 115-136.
- Mueller, BU; Pabst, T; Osato, M; Asou, N; Johansen, LM; Minden, MD; Behre, G; Hiddemann, W; Ito, Y, and Tenen, DG. (2002). Heterozygous PU.1 mutations are associated with acute myeloid leukemia. *Blood* (100) 998-1007.
- Muller, C; Yang, R; Park, DJ; Serve, H; Berdel, WE, and Koeffler, HP. (2000). The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. *Blood* (96) 3894-3899.
- Muller-Tidow, C; Schwable, J; Steffen, B; Tidow, N; Brandt, B; Becker, K; Schulze-Bahr, E; Halfter, H; Vogt, U; Metzger, R; Schneider, PM; Buchner, T; Brandts, C; Berdel, WE, and Serve, H. (2004). High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. *Clin. Cancer Res.* (10) 1241-1249.
- Muntean, AG; Ge, Y; Taub, JW, and Crispino, JD. (2006). Transcription factor GATA-1 and Down syndrome leukemogenesis. *Leuk. Lymphoma* (47) 986-997.
- Murati, A; Adelaide, J; Quilichini, B; Remy, V; Sainty, D; Stoppa, AM; Bernard, P; Olschwang, S; Birnbaum, D; Chaffanet, M, and Mozziconacci, MJ. (2007). New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. *Haematologica* (92) 262-263.

- Nakao, M; Yokota, S; Iwai, T; Kaneko, H; Horiike, S; Kashima, K; Sonoda, Y; Fujimoto, T, and Misawa, S. (1996). Internal tandem duplication of the *flt3* gene found in acute myeloid leukemia. *Leukemia* (10) 1911-1918.
- Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P, and Schoch, C. (2005). Distinct gene expression patterns associated with. *Oncogene* (24) 1580-1588.
- Nerlov, C. (2004). C/EBPalpha mutations in acute myeloid leukaemias. *Nat. Rev. Cancer* (4) 394-400.
- Ning, ZQ; Li, J, and Arceci, RJ. (2001). Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. *Blood* (97) 3559-3567.
- Niu, C; Yan, H; Yu, T; Sun, HP; Liu, JX; Li, XS; Wu, W; Zhang, FQ; Chen, Y; Zhou, L; Li, JM; Zeng, XY; Yang, RR; Yuan, MM; Ren, MY; Gu, FY; Cao, Q; Gu, BW; Su, XY; Chen, GQ; Xiong, SM; Zhang, TD; Waxman, S; Wang, ZY; Chen, Z; Hu, J; Shen, ZX, and Chen, SJ. (1999). Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. *Blood* (94) 3315-3324.
- Novotny, JR; Nuckel, H, and Duhrsen, U. (2006). Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. *Eur. J. Haematol.* (76) 299-308.
- Owens, BM and Hawley, RG. (2002). HOX and non-HOX homeobox genes in leukemic hematopoiesis. *Stem Cells* (20) 364-379.
- Ozeki, K; Kiyoi, H; Hirose, Y; Iwai, M; Ninomiya, M; Kodera, Y; Miyawaki, S; Kuriyama, K; Shimazaki, C; Akiyama, H; Nishimura, M; Motoji, T; Shinagawa, K; Takeshita, A; Ueda, R; Ohno, R; Emi, N, and Naoe, T. (2004). Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. *Blood* (103) 1901-1908.
- Pabst, T; Mueller, BU; Harakawa, N; Schoch, C; Haferlach, T; Behre, G; Hiddemann, W; Zhang, DE, and Tenen, DG. (2001). AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. *Nat. Med.* (7) 444-451.
- Panagopoulos, I; Fioretos, T; Isaksson, M; Mitelman, F; Johansson, B; Theorin, N, and Juliusson, G. (2002). RT-PCR analysis of acute myeloid leukemia with t(8;16)(p11;p13): identification of a novel MOZ/CBP transcript and

- absence of CBP/MOZ expression. *Genes Chromosomes. Cancer* (35) 372-374.
- Panagopoulos, I; Fioretos, T; Isaksson, M; Samuelsson, U; Billstrom, R; Strombeck, B; Mitelman, F, and Johansson, B. (2001). Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). *Hum. Mol. Genet.* (10) 395-404.
- Panagopoulos, I; Isaksson, M; Lindvall, C; Bjorkholm, M; Ahlgren, T; Fioretos, T; Heim, S; Mitelman, F, and Johansson, B. (2000). RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). *Genes Chromosomes. Cancer* (28) 415-424.
- Panagopoulos, I; Isaksson, M; Lindvall, C; Hagemeijer, A; Mitelman, F, and Johansson, B. (2003). Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13). *Genes Chromosomes. Cancer* (36) 90-98.
- Pandolfi, PP. (2001). Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. *Hum. Mol. Genet.* (10) 769-775.
- Park, DJ; Vuong, PT; de Vos, S; Douer, D, and Koeffler, HP. (2003). Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. *Blood* (102) 3727-3736.
- Paschka, P; Marcucci, G; Ruppert, AS; Mrozek, K; Chen, H; Kittles, RA; Vukosavljevic, T; Perrotti, D; Vardiman, JW; Carroll, AJ; Kolitz, JE; Larson, RA, and Bloomfield, CD. (2006). Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. *J. Clin. Oncol.* (24) 3904-3911.
- Pedersen-Bjergaard, J. (2005). Insights into leukemogenesis from therapy-related leukemia. *N. Engl. J. Med.* (352) 1591-1594.
- Pelletier, N; Champagne, N; Lim, H, and Yang, XJ. (2003). Expression, purification, and analysis of MOZ and MORF histone acetyltransferases. *Methods* (31) 24-32.
- Petti, MC; Pinazzi, MB; Diverio, D; Romano, A; Petrucci, MT; De Santis, S; Meloni, G; Tafuri, A; Mandelli, F, and Lo Coco, F. (2001). Prolonged molecular remission in advanced acute promyelocytic leukaemia after

- treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). *Br. J. Haematol.* (115) 63-65.
- Poppe, B; Vandesompele, J; Schoch, C; Lindvall, C; Mrozek, K; Bloomfield, CD; Beverloo, HB; Michaux, L; Dastugue, N; Herens, C; Yigit, N; De Paepe, A; Hagemeijer, A, and Speleman, F. (2004). Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. *Blood* (103) 229-235.
- Porcu, P; Cripe, LD; Ng, EW; Bhatia, S; Danielson, CM; Orazi, A, and McCarthy, LJ. (2000). Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. *Leuk. Lymphoma* (39) 1-18.
- Porcu, P; Farag, S; Marcucci, G; Cataland, SR; Kennedy, MS, and Bissell, M. (2002). Leukocytoreduction for acute leukemia. *Ther. Apher.* (6) 15-23.
- Preudhomme, C; Sagot, C; Boissel, N; Cayuela, JM; Tigaud, I; de Botton, S; Thomas, X; Raffoux, E; Lamandin, C; Castaigne, S; Fenaux, P, and Dombret, H. (2002). Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). *Blood* (100) 2717-2723.
- Quesnel, B; Kantarjian, H; Bjergaard, JP; Brault, P; Estey, E; Lai, JL; Tilly, H; Stoppa, AM; Archimbaud, E, and Harousseau, JL. (1993). Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. *J. Clin. Oncol.* (11) 2370-2379.
- Rebel, VI; Kung, AL; Tanner, EA; Yang, H; Bronson, RT, and Livingston, DM. (2002). Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. *Proc. Natl. Acad. Sci. U. S. A* (99) 14789-14794.
- Redner, RL. (2002). Variations on a theme: the alternate translocations in APL. *Leukemia* (16) 1927-1932.
- Roche, J; Zeng, C; Baron, A; Gadgil, S; Gemmill, RM; Tigaud, I; Thomas, X, and Drabkin, HA. (2004). Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. *Leukemia* (18) 1059-1063.
- Rowley, JD; Reshmi, S; Sobulo, O; Musvee, T; Anastasi, J; Raimondi, S; Schneider, NR; Barredo, JC; Cantu, ES; Schlegelberger, B; Behm, F; Doggett, NA; Borrow, J, and Zeleznik-Le, N. (1997). All patients with

the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. *Blood* (90) 535-541.

- Sanz, MA; Lo Coco, F; Martin, G; Avvisati, G; Rayon, C; Barbui, T; Díaz-Mediavilla, J; Fioritoni, G; Gonzalez, JD; Liso, V; Esteve, J; Ferrara, F; Bolufer, P; Bernasconi, C; Gonzalez, M; Rodeghiero, F; Colomer, D; Petti, MC; Ribera, JM, and Mandelli, F. (2000). Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. *Blood* (96) 1247-1253.
- Sanz, MA; Martin, G; Gonzalez, M; Leon, A; Rayon, C; Rivas, C; Colomer, D; Amutio, E; Capote, FJ; Milone, GA; De La Serna, J; Roman, J; Barragan, E; Bergua, J; Escoda, L; Parody, R; Negri, S; Calasanz, MJ, and Bolufer, P. (2004). Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. *Blood* (103) 1237-1243.
- Sanz, MA; Martin, G; Rayon, C; Esteve, J; Gonzalez, M; Díaz-Mediavilla, J; Bolufer, P; Barragan, E; Terol, MJ; Gonzalez, JD; Colomer, D; Chillon, C; Rivas, C; Gomez, T; Ribera, JM; Bornstein, R; Roman, J; Calasanz, MJ; Arias, J; Alvarez, C; Ramos, F, and Deben, G. (1999). A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. *Blood* (94) 3015-3021.
- Satake, N; Maseki, N; Nishiyama, M; Kobayashi, H; Sakurai, M; Inaba, H; Katano, N; Horikoshi, Y; Eguchi, H; Miyake, M; Seto, M, and Kaneko, Y. (1999). Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. *Leukemia* (13) 1013-1017.
- Schlenk, RF; Benner, A; Krauter, J; Buchner, T; Sauerland, C; Ehninger, G; Schaich, M; Mohr, B; Niederwieser, D; Krahl, R; Pasold, R; Dohner, K; Ganser, A; Dohner, H, and Heil, G. (2004). Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. *J. Clin. Oncol.* (22) 3741-3750.
- Schmidt, HH; Strehl, S; Thaler, D; Strunk, D; Sill, H; Linkesch, W; Jager, U; Sperr, W; Greinix, HT; Konig, M; Emberger, W, and Haas, OA. (2004). RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. *Leukemia* (18) 1115-1121.
- Schnittger, S; Kinkelin, U; Schoch, C; Heinecke, A; Haase, D; Haferlach, T; Buchner, T; Wormann, B; Hiddemann, W, and Griesinger, F. (2000). Screening for MLL tandem duplication in 387 unselected patients with

AML identify a prognostically unfavorable subset of AML. *Leukemia* (14) 796-804.

Schnittger, S; Schoch, C; Dugas, M; Kern, W; Staib, P; Wuchter, C; Loffler, H; Sauerland, CM; Serve, H; Buchner, T; Haferlach, T, and Hiddemann, W. (2002). Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. *Blood* (100) 59-66.

Schnittger, S; Schoch, C; Kern, W; Mecucci, C; Tschulik, C; Martelli, MF; Haferlach, T; Hiddemann, W, and Falini, B. (2005). Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. *Blood* (106) 3733-3739.

Schoch, C; Kohlmann, A; Schnittger, S; Brors, B; Dugas, M; Mergenthaler, S; Kern, W; Hiddemann, W; Eils, R, and Haferlach, T. (2002). Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. *Proc. Natl. Acad. Sci. U. S. A* (99) 10008-10013.

Schoch, C; Schnittger, S; Klaus, M; Kern, W; Hiddemann, W, and Haferlach, T. (2003). AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. *Blood* (102) 2395-2402.

Second MIC Cooperative Study Group. (1988). Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Report of the Workshop held in Leuven, Belgium, September 15-17, 1986. Second MIC Cooperative Study Group. *Cancer Genet. Cytogenet.* (30) 1-15.

Serrano, E; Lasa, A; Perea, G; Carnicer, MJ; Brunet, S; Aventin, A; Sierra, J, and Nomdedeu, JF. (2006). Acute Myeloid Leukemia Subgroups Identified by Pathway-Restricted Gene Expression Signatures. *Acta Haematol.* (116) 77-89.

Shen, WF; Krishnan, K; Lawrence, HJ, and Largman, C. (2001). The HOX homeodomain proteins block CBP histone acetyltransferase activity. *Mol. Cell Biol.* (21) 7509-7522.

Shepherd, JD; Barnett, MJ, and Philips, GL. (1996). High-dose cytarabine induction for acute myeloid leukemia. *Blood* (88) 754-755.

- Shigesada, K; van de Sluis, B, and Liu, PP. (2004). Mechanism of leukemogenesis by the inv(16) chimeric gene CBFβ/PEBP2B-MHY11. *Oncogene* (23) 4297-4307.
- Slovak, ML; Kopecky, KJ; Cassileth, PA; Harrington, DH; Theil, KS; Mohamed, A; Paietta, E; Willman, CL; Head, DR; Rowe, JM; Forman, SJ, and Appelbaum, FR. (2000). Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. *Blood* (96) 4075-4083.
- So, CW and Cleary, ML. (2003). Common mechanism for oncogenic activation of MLL by forkhead family proteins. *Blood* (101) 633-639.
- Soignet, SL; Frankel, SR; Douer, D; Tallman, MS; Kantarjian, H; Calleja, E; Stone, RM; Kalaycio, M; Scheinberg, DA; Steinherz, P; Sievers, EL; Coutre, S; Dahlberg, S; Ellison, R, and Warrell, RP, Jr. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. *J. Clin. Oncol.* (19) 3852-3860.
- Song, JH; Choi, CH; Yeom, HJ; Hwang, SY, and Kim, TS. (2006). Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis. *Life Sci.* (79) 193-202.
- Speck, NA and Gilliland, DG. (2002). Core-binding factors in haematopoiesis and leukaemia. *Nat. Rev. Cancer* (2) 502-513.
- Spiekermann, K; Biethahn, S; Wilde, S; Hiddemann, W, and Alves, F. (2001). Constitutive activation of STAT transcription factors in acute myelogenous leukemia. *Eur. J. Haematol.* (67) 63-71.
- Stacchini, A; Fubini, L; Severino, A; Sanavio, F; Aglietta, M, and Piacibello, W. (1996). Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. *Leukemia* (10) 1584-1591.
- Stark, B; Resnitzky, P; Jeison, M; Luria, D; Blau, O; Avigad, S; Shaft, D; Kodman, Y; Gobuzov, R, and Ash, S. (1995). A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11;q13)--case report and review of the literature. *Leuk. Res.* (19) 367-379.
- Steffen, B; Muller-Tidow, C; Schwable, J; Berdel, WE, and Serve, H. (2005). The molecular pathogenesis of acute myeloid leukemia. *Crit Rev. Oncol. Hematol.* (56) 195-221.

- Steudel, C; Wermke, M; Schaich, M; Schakel, U; Illmer, T; Ehninger, G, and Thiede, C. (2003). Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. *Genes Chromosomes. Cancer* (37) 237-251.
- Stirewalt, DL; Kopecky, KJ; Meshinchi, S; Engel, JH; Pogossova-Agadjanyan, EL; Linsley, J; Slovak, ML; Willman, CL, and Radich, JP. (2006). Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood* (107) 3724-3726.
- Suciu, S; Mandelli, F; de Witte, T; Zittoun, R; Gallo, E; Labar, B; De Rosa, G; Belhabri, A; Giustolisi, R; Delarue, R; Liso, V; Mirto, S; Leone, G; Bourhis, JH; Fioritoni, G; Jehn, U; Amadori, S; Fazi, P; Hagemeijer, A, and Willemze, R. (2003). Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. *Blood* (102) 1232-1240.
- Sun, T and Wu, E. (2001). Acute monoblastic leukemia with t(8;16): a distinct clinicopathologic entity; report of a case and review of the literature. *Am. J. Hematol.* (66) 207-212.
- Tallman, MS. (2004). Acute promyelocytic leukemia as a paradigm for targeted therapy. *Semin. Hematol.* (41) 27-32.
- Tallman, MS. (2005). New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. *Hematology. (Am. Soc. Hematol. Educ. Program.)* 143-150.
- Tallman, MS. (2006). New agents for the treatment of acute myeloid leukemia. *Best. Pract. Res. Clin. Haematol.* (19) 311-320.
- Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Woods, WG; Ogden, A; Weinstein, H; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM, and Wiernik, PH. (2002). All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. *Blood* (100) 4298-4302.
- Tasaka, T; Matsushashi, Y; Uehara, E; Tamura, T; Kakazu, N; Abe, T, and Nagai, M. (2004). Secondary acute monocytic leukemia with a translocation t(8;16)(p11;p13): case report and review of the literature. *Leuk. Lymphoma* (45) 621-625.

- Tenen, DG. (2003). Disruption of differentiation in human cancer: AML shows the way. *Nat. Rev. Cancer* (3) 89-101.
- Thiede, C; Koch, S; Creutzig, E; Steudel, C; Illmer, T; Schaich, M, and Ehninger, G. (2006). Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood* (107) 4011-4020.
- Thiede, C; Steudel, C; Mohr, B; Schaich, M; Schakel, U; Platzbecker, U; Wermke, M; Bornhauser, M; Ritter, M; Neubauer, A; Ehninger, G, and Illmer, T. (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. *Blood* (99) 4326-4335.
- Thomas, T; Corcoran, LM; Gugasyan, R; Dixon, MP; Brodnicki, T; Nutt, SL; Metcalf, D, and Voss, AK. (2006a). Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. *Genes & Dev.* (20) 1175-1186.
- Thomas, X; Pigneux, A; Raffoux, E; Huguet, F; Caillot, D, and Fenaux, P. (2006b). Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. *Haematologica* (91) 996-997.
- Tischkowitz, M and Dokal, I. (2004). Fanconi anaemia and leukaemia - clinical and molecular aspects. *Br. J. Haematol.* (126) 176-191.
- Troke, PJ; Kindle, KB; Collins, HM, and Heery, DM. (2006). MOZ fusion proteins in acute myeloid leukaemia. *Biochem. Soc. Symp.* 23-39.
- Tse, KF; Mukherjee, G, and Small, D. (2000). Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. *Leukemia* (14) 1766-1776.
- Valk, PJ; Delwel, R, and Lowenberg, B. (2005). Gene expression profiling in acute myeloid leukemia. *Curr. Opin. Hematol.* (12) 76-81.
- Valk, PJ; Verhaak, RG; Beijen, MA; Erpelinck, CA; Barjesteh van Waalwijk van Doorn-Khosrovani; Boer, JM; Beverloo, HB; Moorhouse, MJ; van der Spek, PJ; Lowenberg, B, and Delwel, R. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. *N. Engl. J. Med.* (350) 1617-1628.
- Vardiman, JW; Harris, NL, and Brunning, RD. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* (100) 2292-2302.

- Velloso, ER; Mecucci, C; Michaux, L; Van Orshoven, A; Stul, M; Boogaerts, M; Bosly, A; Cassiman, JJ, and Van Den Berghe, H. (1996). Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature. *Leuk. Lymphoma* (21) 137-142.
- Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D, and Bertucci, F. (2004). Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. *Oncogene* (23) 9381-9391.
- Visani, G; Olivieri, A; Malagola, M; Brunori, M; Piccaluga, PP; Capelli, D; Pomponio, G; Martinelli, G; Isidori, A; Sparaventi, G, and Leoni, P. (2006). Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. *Leuk. Lymphoma* (47) 1091-1102.
- Visser, M; Hofstra, RM; Stulp, RP; Wu, Y; Buys, CH; Willemze, R, and Landegent, JE. (1997). Absence of mutations in the RET gene in acute myeloid leukemia. *Ann. Hematol.* (75) 87-90.
- Vizmanos, JL; Larrayoz, MJ; Lahortiga, I; Floristan, F; Alvarez, C; Otero, MD; Novo, FJ, and Calasanz, MJ. (2003). t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. *Genes Chromosomes. Cancer* (36) 402-405.
- von Mikecz, A; Zhang, S; Montminy, M; Tan, EM, and Hemmerich, P. (2000). CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. *J. Cell Biol.* (150) 265-273.
- Welte, K; Zeidler, C, and Dale, DC. (2006). Severe congenital neutropenia. *Semin. Hematol.* (43) 189-195.
- Westendorf, JJ; Yamamoto, CM; Lenny, N; Downing, JR; Selsted, ME, and Hiebert, SW. (1998). The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. *Mol. Cell Biol.* (18) 322-333.
- Whitman, SP; Archer, KJ; Feng, L; Baldus, C; Becknell, B; Carlson, BD; Carroll, AJ; Mrozek, K; Vardiman, JW; George, SL; Kolitz, JE; Larson, RA; Bloomfield, CD, and Caligiuri, MA. (2001). Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. *Cancer Res.* (61) 7233-7239.

- Yamamoto, Y; Kiyoi, H; Nakano, Y; Suzuki, R; Kodera, Y; Miyawaki, S; Asou, N; Kuriyama, K; Yagasaki, F; Shimazaki, C; Akiyama, H; Saito, K; Nishimura, M; Motoji, T; Shinagawa, K; Takeshita, A; Saito, H; Ueda, R; Ohno, R, and Naoe, T. (2001). Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. *Blood* (97) 2434-2439.
- Yokoyama, A; Somerville, TC; Smith, KS; Rozenblatt-Rosen, O; Meyerson, M, and Cleary, ML. (2005). The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. *Cell* (123) 207-218.
- Yokoyama, A; Wang, Z; Wysocka, J; Sanyal, M; Aufiero, DJ; Kitabayashi, I; Herr, W, and Cleary, ML. (2004). Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. *Mol. Cell Biol.* (24) 5639-5649.
- Zhang, X; Zhou, H; Wang, J; Yang, L; Hu, Y; Shen, G; Guo, P; Qiao, Z, and Song, S. (2002). Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. *Thromb. Res.* (106) 63-70.